文献速递临床免疫质量管理与危急值

Alinity i 他克莫司 CMIA 与两家参考实验室 LC-MS/MS 的相关性

Good correlation between tacrolimus concentrations using improved CMIA on the Alinity i analyzer and LC-MS/MS method from a reference laboratory but unexpected negative bias with another LC-MS/MS method from a different reference laboratory.
PubMed 文献 · Am J Clin Pathol · 2024-01-01

研究比较 Alinity i 分析仪上他克莫司 CMIA 与两家参考实验室 LC-MS/MS 法的浓度,并比较 CMIA 与 Elecsys 法。CMIA 总精密度极佳;与参考实验室 A 的 LC-MS/MS 法回归方程为 y=0.9721x+1.005(r=0.95),无显著偏倚;与参考实验室 B 的 LC-MS/MS 法回归方程为 y=0.7664x+1.775(r=0.93),CMIA 呈显著负偏倚;CMIA 与 Elecsys 免疫法结果可比。结论认为 Alinity i 上 CMIA 可用于他克莫司治疗药物监测。

要点

  • Alinity i 他克莫司 CMIA 总精密度极佳。
  • 与参考实验室 A 的 LC-MS/MS 法相关性好,无显著偏倚。
  • 与参考实验室 B 的 LC-MS/MS 法比较,CMIA 呈显著负偏倚。

核心结论

  • Alinity i 上 CMIA 他克莫司与参考实验室 A 的 LC-MS/MS 法相关性好,可用于治疗药物监测。

研究设计与样本

  • 用 EDTA 全血测量他克莫司浓度:Alinity i 上 CMIA 法,另两份等分样本送两家参考实验室,均用 ascomycin 作内标的 LC-MS/MS 法。

主要发现

  • CMIA 他克莫司总精密度极佳。
  • 以参考实验室 A 的 LC-MS/MS 值为 x 轴、对应 CMIA 值为 y 轴,回归方程 y=0.9721x+1.005(r=0.95),CMIA 无显著偏倚。
  • 以参考实验室 B 的 LC-MS/MS 值为对照,回归方程 y=0.7664x+1.775(r=0.93),CMIA 呈显著负偏倚。
  • 参考实验室 B 的他克莫司浓度相对参考实验室 A 呈正偏倚。
  • CMIA 与 Elecsys 免疫法测得的他克莫司浓度可比。

临床怎么用

  • 因与长期参考实验室 A 的 LC-MS/MS 法相关性好,Alinity i 上 CMIA 可用于他克莫司治疗药物监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We compared tacrolimus concentrations obtained by the more recently US Food and Drug Administration-approved tacrolimus assay (CMIA) on the Alinity i analyzer (Abbott Laboratories) with a liquid chromatography/tandem mass spectrometry (LC-MS/MS)-based method from 2 reference laboratories. We also investigated the correlation between the CMIA tacrolimus and Elecsys tacrolimus assays. METHODS: Tacrolimus concentrations were measured in EDTA whole blood by the chemiluminescent microparticle immunoassay (CMIA) using the Alinity i analyzer, and then 2 aliquots were sent to 2 reference laboratories, both using ascomycin as the internal standard for the LC-MS/MS method. RESULTS: The total precision of the CMIA tacrolimus assay was excellent. When tacrolimus concentrations obtained by the LC-MS/MS method from reference laboratory A were plotted on the x-axis and corresponding CMIA values were plotted on the y-axis, the following regression equation was observed: y = 0.9721x + 1.005 (r = 0.95), indicating no significant bias with the CMIA. However, when tacrolimus values obtained from reference laboratory B were used for comparison, the regression equation was y = 0.7664x + 1.775 (r = 0.93), indicating significant negative bias with the CMIA. When we compared tacrolimus concentrations obtained by reference laboratories A and B, we observed positive bias with tacrolimus concentrations obtained by reference laboratory B. However, tacrolimus concentrations obtained by both CMIA and Elecsys immunoassays were comparable. CONCLUSIONS: Because of good correlation of tacrolimus concentrations using the CMIA and LC-MS/MS from reference laboratory A, our long-term reference laboratory for drug analysis, we concluded that the CMIA on the Alinity i can be used for therapeutic drug monitoring of tacrolimus.

来源:Am J Clin Pathol,查看原文。版权归原作者所有。

引用

  1. Woodard K, Kisler T, Dasgupta A, et al. Good correlation between tacrolimus concentrations using improved CMIA on the Alinity i analyzer and LC-MS/MS method from a reference laboratory but unexpected negative bias with another LC-MS/MS method from a different reference laboratory. Am J Clin Pathol. 2024. PMID: 38346092. doi:10.1093/ajcp/aqae005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。